Clinical trials: Influenza Virus Infection
Influenza
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
The purpose of this study is to see how much antibody (proteins produced by the immune system that help fight infections) the body makes after getting a flu vaccine.
- Trial name
- NCT01173211
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Young Adult Influenza Vaccine Immunogenicity Substudy
This is a complimentary study to an elderly influenza study. Subjects 18-40 will receive a single dose flu vaccine and be evaluated for humoral and cell mediated immunity to influenza antigens.
- Trial name
- NCT00170508
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Orthomyxovirus Infection
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects.
- Conditions
- Influenza, Orthomyxovirus Infection, Myxovirus Infection
- Trial name
- NCT00775450
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 28 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy
Pregnancy, Arsenic and Immune Response
As the global availability of vaccines increases, and reaches areas disproportionately affected by arsenic and malnutrition, resolving questions about potential environmental and biologic barriers to maternal immunization has…
- Conditions
- Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired, Micronutrient Deficiency
- Trial name
- PAIR (NCT03930017)
- Testing
- Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)
- Where
- Bangladesh
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Seasonal Influenza
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
- Trial name
- IGNITE P303 (NCT05827978)
- Testing
- mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
- Where
- 103 sites in United States
- Volunteers
- 8,411 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
This study will assess the pharmacokinetics/pharmacodynamics and safety of oseltamivir [Tamiflu] therapy in infants less than 1 year of age with influenza diagnosed in the 96 hours prior to the first dose.
- Trial name
- NCT00988325
- Testing
- Tamiflu
- Where
- 12 sites in Belgium, France and 4 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Human Influenza
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each influenza…
- Trial name
- NCT01885117
- Testing
- TIVf
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Influenza Vaccine Trial in HIV Uninfected Pregnant Women
Randomised, double blind, placebo controlled trial to assess safety, immunogenicity and efficacy of Trivalent Influenza vaccine in HIV uninfected pregnant women
- Trial name
- MatfluHIVneg (NCT01306669)
- Testing
- Trivalent influenza vaccine, Normal saline
- Where
- South Africa
- Volunteers
- 2,116 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
HIV, Influenza
Efficacy of Influenza Vaccine in HIV Infected Adults
Vaccination of HIV infected individuals with the sub-unit influenza vaccine is safe; however it induces only moderate immune responses and likewise is modest in its protection compared to HIV uninfected individuals.
- Conditions
- HIV, Influenza, Vaccination, HIV Infections
- Trial name
- NCT00757900
- Testing
- MUTAGRIP
- Where
- South Africa
- Volunteers
- 507 people
- Sponsor
- University of Witwatersrand, South Africa
Influenza, COVID-19
Enhancing Protection Against Influenza and COVID-19 for Pregnant Women and Medically at Risk Children
Pregnant women and children with chronic medical conditions are at increased risk of hospitalisation, intensive care admission and death from influenza and COVID-19 infections.
- Trial name
- NCT05613751
- Testing
- Nudge
- Where
- 7 sites in Australia
- Volunteers
- 1,038 people
- Sponsor
- University of Adelaide
Respiratory Viral Infection
Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza
A multicenter, randomized, double-blind, positive controlled, phase III trial to evaluate the safety and efficacy of ZX-7101A tablets versus oseltamivir phosphate suspension in children aged ≥5 years and < 12 years with…
- Trial name
- ZX-7101A-210 (NCT06669351)
- Testing
- ZX-7101A, Oseltamivir phosphate dry suspension
- Where
- 3 sites in China
- Volunteers
- 98 people
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Prematurity of Fetus
Pharmacokinetics of Oseltamivir in Newborns and Infants
Oseltamivir dosing in infants < 3 months of age is based on a single pharmacokinetic study in 20 infants from a single center. This dataset is limited by a lack of robustness, because only 1 sample was collected from each…
- Trial name
- NCT01388439
- Testing
- Oseltamivir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- St. Louis Children's Hospital
Influenza
Immunogenicity of Influenza Vaccinations
This study is a randomized immunogenicity study in an enrolled cohort with active surveillance for influenza-like illness (ILI).
- Trial name
- NCT06518577
- Testing
- Flucelvax® (ccIIV3), Flublok® (RIV3)
- Where
- 7 sites in United States
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza, Vaccine
Influenza Vaccine Postpartum Questionnaire
The purpose of this trial is to assess the knowledge and attitudes of post-partum women regarding influenza and the use of the influenza vaccine in pregnancy.
- Conditions
- Influenza, Vaccine, Pregnancy
- Trial name
- NCT00401700
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Influenza
The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old
This trial by its design was a prospective, multicenter, double blind, randomized comparative clinical trial of the IIIb-IV phase which was carried out in parallel groups of volunteers over the age of 60
- Trial name
- NCT05089123
- Testing
- Flu-M [Inactivated split influenza vaccine], Inactivated Split Influenza Vaccine
- Where
- 2 sites in Russia
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous…
- Trial name
- NCT01048879
- Testing
- pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Influenza
Phase II Study of Pandemic Influenza Vaccine
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic.
- Trial name
- NCT00320346
- Testing
- Pandemic Influenza Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
High-risk Influenza Vaccine Alert
The purpose of this study is to assess, prospectively, the effect on flu vaccination rates of salient alerts in the electronic health record that indicate a patient's high risk for flu and its complications.
- Trial name
- NCT05492786
- Testing
- Alert, Salient alert features, High-risk Text
- Where
- United States
- Volunteers
- 80,452 people
- Sponsor
- Geisinger Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.